Is It Possible to Prevent Bone Loss in Young Women Treated with Luteinizing Hormone-Releasing Hormone Agonists?
- 1 April 1990
- journal article
- research article
- Published by The Endocrine Society in Journal of Clinical Endocrinology & Metabolism
- Vol. 70 (4), 920-924
- https://doi.org/10.1210/jcem-70-4-920
Abstract
Recent studies have shown that treatment with the LHRH agonist nafarelin gives symptomatic and objective relief to women with endometriosis. Such a treatment, however, results in increased bone turnover and loss of bone mass. In the present study 17 women with endometriosis were treated with 400 mg nafarelin combined with 1.2 mg norethisterone (NET) for 6 months, followed by 6 months with only 1.2 mg NET. The data were compared to data from a previously published study of 9 women treated for 6 months with 400 mg nafarelin alone, followed by 6 months without treatment. In the group treated with nafarelin plus NET the biochemical parameter of bone resorption (fasting urinary hydroxyproline) remained virtually unchanged, compared to a highly significant increase in the nafarelin-treated group. Estimates of bone formation (serum alkaline phosphatase and plasma bone Gla protein) increased in the nafarelin plus NET group, but to only a minor extent compared to those in the nafarelin group. In addition, bone mineral in the forearm, the spine, and the total skeleton remained virtually unchanged in the group treated with nafarelin plus NET, compared to the bone loss of 2-6%/6 months in the nafarelin group. We conclude that addition of NET to nafarelin treatment of endometriosis seems to have a bone-sparing effect.This publication has 9 references indexed in Scilit:
- Long-term and withdrawal effects of two different oestrogen-progestogen combinations on lipid and lipoprotein profiles in post-menopausal womenMaturitas, 1989
- The Effect of a Gonadotropin-Releasing Hormone Agonist Analog (Nafarelin) on Bone MetabolismJournal of Clinical Endocrinology & Metabolism, 1988
- Continuous oestrogen-progestogen treatment and bone metabolism in post-menopausal womenMaturitas, 1988
- Administration of Nasal Nafarelin as Compared with Oral Danazol for EndometriosisNew England Journal of Medicine, 1988
- A radioimmunoassay for bone Gla protein (BGP) in human plasmaActa Endocrinologica, 1987
- UNCOUPLING OF BONE FORMATION AND RESORPTION BY COMBINED OESTROGEN AND PROGESTAGEN THERAPY IN POSTMENOPAUSAL OSTEOPOROSISThe Lancet, 1985
- COMPARISON OF SINGLE-PHOTON AND DUAL-PHOTON ABSORPTIOMETRY IN POSTMENOPAUSAL BONE-MINERAL LOSS1985
- Total body bone mineral in vivo by dual photon absorptiometry. I. Measurement proceduresClinical Physiology and Functional Imaging, 1984
- BONE MASS IN POSTMENOPAUSAL WOMEN AFTER WITHDRAWAL OF OESTROGEN/GESTAGEN REPLACEMENT THERAPYThe Lancet, 1981